Ivermectin; defining term; allowing ivermectin to be sold or purchased without prescription; immunity for pharmacy; effective date.
Summary
HB4124 creates a new section of Oklahoma law allowing FDA-approved ivermectin suitable for human use to be sold and purchased over the counter, without a prescription or consultation with a health care professional. The bill defines “over-the-counter medication” for this purpose and expressly states that ivermectin may be sold or purchased in the state notwithstanding any contrary law.
The measure also provides that pharmacies are not criminally or civilly liable for supplying ivermectin in accordance with the new law. The bill is set to take effect on November 1, 2026, and would be codified in Title 59 of the Oklahoma Statutes.
Impact
If enacted, HB4124 would change Oklahoma’s pharmacy and drug-dispensing rules by carving out ivermectin from prescription-only status, but only for FDA-approved ivermectin suitable for human use. It would affect pharmacies, pharmacists, consumers seeking access to ivermectin, and any state laws or regulations that currently require a prescription or professional consultation before dispensing the drug. The bill also adds liability protection for pharmacies that comply with the statute.
Sentiment
The bill appears to have received generally favorable treatment in committee and on the House floor, advancing through the Public Health Committee, the Health and Human Services Oversight Committee, and passing third reading in the House by a substantial margin. The committee transcript is brief and procedural, but the recorded votes suggest the measure had meaningful support while still drawing some opposition.
Contention
The main point of contention is the policy choice to make ivermectin available without a prescription, which implicates pharmacy practice, patient safety, and the role of health care professionals in dispensing medication. Supporters appear to favor broader access and legal protection for pharmacies, while opponents likely object to removing prescription and consultation requirements for a drug that has been controversial in medical and public health debates. The recorded committee and floor votes show that the bill was not unanimous, indicating some division over these issues.